TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid («mRNA») today announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has
— Weiterlesen www.accesswire.com/707530/CureVac-Files-Patent-Infringement-Lawsuit-in-Germany-Against-BioNTech
lückenpresse 